spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  uric acid 

 HSMN NewsFeed - 15 Dec 2025
Sobi to Acquire Arthrosi Therapeutics, Strengthening Pipeline for the Potential Treatment of Gout
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2024
ZWI Therapeutics, Inc. Announces a Series A Financing, Two Accomplished Biopharmaceutical CEOs Join the Board of Directors, and Appointment of Chief Executive Officer
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 6 Oct 2023
Amgen Completes Acquisition of Horizon Therapeutics plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 May 2020
Acquist Therapeutics Announces New Appointments to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jan 2020
ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Nov 2017
Noden Pharma Announces FDA Approval of Tekturna(R) (aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 5 Jul 2017
Recordati Rare Diseases Introduces New PANHEMATIN(R) (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2013
Mission Pharmacal Launches Dedicated Sales Force
Biopharmaceuticals Urology Distribution
 HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA
 HSMN NewsFeed - 9 May 2013
Cornerstone Therapeutics Acquires Exclusive U.S. Marketing Rights to PERTZYE(R) (pancrelipase) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Cystic Fibrosis
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 19 Oct 2012
Savient Receives Positive CHMP Opinion for KRYSTEXXA(R) Approval in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Apr 2012
AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Apr 2012
Takeda to Acquire URL Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Mar 2012
Savient Announces Named Patient Programme for KRYSTEXXA(R) in the European Union for Patients with Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jan 2012
Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 3 Nov 2011
Savient Pharmaceuticals Receives J-code for KRYSTEXXA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 May 2011
Teijin Pharma to Launch Feburic(r) (febuxostat) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 7 Jan 2011
Savient Pharmaceuticals Provides Business Update
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2010
FDA Approves New Drug Application for PANCREAZE(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2010
Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2009
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2009
FDA Approves Colcrys(TM) (colchicine, USP) for Prevention of Gout Flares
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Oct 2009
FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Aug 2009
Eurand Granted FDA Approval for ZENPEP(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2009
FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2009
ULORIC(R) (febuxostat) 40-mg and 80-mg Tablets Now Available for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2009
FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jul 2008
TREDAPTIVE(TM) (nicotinic acid /laropiprant) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 13 May 2008
Siemens Introduces Dual Energy Applications for General Imaging
Devices Radiology
 HSMN NewsFeed - 5 May 2008
Ipsen: Adenuric(R) (Febuxostat) Receives Marketing Authorisation in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Mar 2008
Siemens Introduces New Dual Energy Applications to SOMATOM Definition
Devices Radiology
 HSMN NewsFeed - 28 Feb 2008
Savient Provides Further Information on Top Line Phase 3 Trials Results for Puricase(R) (pegloticase)
Biopharmaceuticals
 HSMN NewsFeed - 21 Feb 2008
EMEA Recommends Marketing Authorisation of Ipsen's Adenuric(R) (Febuxostat) for the Treatment of Chronic Hyperuricaemia in Gout
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Dec 2007
Puricase(R) (pegloticase) Meets Pre-Specified Primary Efficacy Endpoint in Two Replicate Phase 3 Studies
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2007
Savient Pharmaceuticals Completes Puricase(R) Phase 3 Studies for Treatment-Failure Gout
Biopharmaceuticals
 HSMN NewsFeed - 20 Aug 2007
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 19 Jul 2007
Schering-Plough Announces Licensing of Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 22 Mar 2007
Abaxis Announces CLIA Waived Status for Two Additional Medical Test Panels
Diagnostics FDA
 HSMN NewsFeed - 6 Mar 2007
Savient Announces Completion of Patient Enrollment in Phase 3 Trials of Puricase(R) for Treatment-Failure Gout
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2006
Ipsen: EMEA's Validation of Febuxostat's Marketing Authorization Application in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Sep 2006
OVATION and Cardinal Health Announce FDA Approval Letter for Manufacturing of Biologic Therapy To Treat Rare Genetic Disorder
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
uric acid
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!